Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy with PD-1 Inhibitor, GM-CSF, and IL-2 in Advanced Refractory Solid Tumors
NCT04892498Phase 2Unknown
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- May 2021
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoint: Progression-Free Survival up to 3 years. Status: unknown.
Beyond the preview
Go deeper on NCT04892498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892498.